RT Journal Article SR Electronic T1 Evolutionary dynamics at the tumor edge reveals metabolic imaging biomarkers JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.06.20204461 DO 10.1101/2020.10.06.20204461 A1 Juan Jiménez-Sánchez A1 Jesús J. Bosque A1 Germán A. Jiménez Londoño A1 David Molina-García A1 Álvaro Martínez A1 Julián Pérez-Beteta A1 Carmen Ortega-Sabater A1 Antonio F. Honguero Martínez A1 Ana M. García Vicente A1 Gabriel F. Calvo A1 Víctor M. Pérez-García YR 2020 UL http://medrxiv.org/content/early/2020/10/07/2020.10.06.20204461.abstract AB Human cancers are biologically and morphologically heterogeneous. A variety of clonal populations emerge within these neoplasms and their interaction leads to complex spatio-temporal dynamics during tumor growth. We studied the reshaping of metabolic activity in human cancers by means of continuous and discrete mathematical models, and matched the results to positron emission tomography (PET) imaging data. Our models revealed that the location of increasingly active proliferative cellular spots progressively drifted from the center of the tumor to the periphery, as a result of the competition between gradually more aggressive phenotypes. This computational finding led to the development of a metric, the NPAC, based on the distance from the location of peak activity (proliferation) to the tumor centroid. The NPAC metric can be computed for human patients using 18F-FDG PET/CT images where the voxel of maximum uptake (SUVmax) is taken as the point of peak activity. Two datasets of 18F-FDG PET/CT images were collected, one from 61 breast cancer patients and another from 161 non-small-cell lung cancer patients. In both cohorts, survival analyses were carried out for the NPAC and for other classical PET/CT-based biomarkers, finding that the former had a high prognostic value, outperforming the latter. In summary, our work offers new insights into the evolutionary mechanisms behind tumor progression and provides a PET/CT-based biomarker with clinical applicability.Significance Statement Through the use of different in silico modeling approaches capturing tumor heterogeneity, we predicted that areas of high metabolic activity would shift towards the periphery as tumors become more malignant. To confirm the prediction and provide clinical value for the finding, we took 18F-FDG PET images of breast cancers and non-small-cell lung cancers, where we measured the distance from the point of maximum activity to the tumor centroid, and normalized it by a surrogate of the volume. We show that this metric has a high prognostic value for both malignancies and outperforms other classical PET-based metabolic biomarkers used in oncology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research has been supported by the James S. McDonnell Foundation 21st Century Science Initiative in Mathematical and Complex Systems Approaches for Brain Cancer (collaborative awards 220020560 and 220020450), Ministerio de Economía y Competitividad/FEDER, Spain (grant no. MTM2015-71200-R) AND Junta de Comunidades de Castilla-La Mancha (grant no. SBPLY/17/180501/000154).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients were participants of a multicentre prospective study approved by the institutional review board (IRB) of Hospital General Universitario de Ciudad Real, Spain. Written informed consent was obtained from all of the patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript and supporting information.